drug
CETIRIZINE HYDROCHLORIDE
Marketedupdated 3mo agoby PL Developments Copiague LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugZyrtec74 co-mentions · 31 sources
- tagApproval72 co-mentions · 28 sources
- drugcetirizine hydrochloride ODT55 co-mentions · 31 sources
- drugCetirizine Hydrochloride Bionpharma55 co-mentions · 31 sources
- drugCETIRIZINE HYDROCHLORIDE ALLERGY55 co-mentions · 31 sources
- tagSmall Molecule36 co-mentions · 28 sources
- tagRecall3 co-mentions · 3 sources
- companyRising Pharma Holdings Inc2 co-mentions · 2 sources
all catalysts(7)
approval · 7
Jul 23, 2009
approval
CETIRIZINE HYDROCHLORIDE ALLERGY (CETIRIZINE HYDROCHLORIDE) — FDA approval
CETIRIZINE HYDROCHLORIDE
→
Apr 6, 2010
approval
CETIRIZINE HYDROCHLORIDE ALLERGY (CETIRIZINE HYDROCHLORIDE) — FDA approval
CETIRIZINE HYDROCHLORIDE
→
Feb 6, 2013
approval
CETIRIZINE HYDROCHLORIDE ALLERGY (CETIRIZINE HYDROCHLORIDE) — FDA approval
CETIRIZINE HYDROCHLORIDE
→
Dec 13, 2019
approval
CETIRIZINE HYDROCHLORIDE ALLERGY (CETIRIZINE HYDROCHLORIDE) — FDA approval
CETIRIZINE HYDROCHLORIDE
→
Dec 7, 2020
approval
CETIRIZINE HYDROCHLORIDE ALLERGY (CETIRIZINE HYDROCHLORIDE) — FDA approval
CETIRIZINE HYDROCHLORIDE
→
Jan 30, 2026
approval
CETIRIZINE HYDROCHLORIDE ALLERGY (CETIRIZINE HYDROCHLORIDE) — FDA approval
CETIRIZINE HYDROCHLORIDE
→
Feb 25, 2026
approval
CETIRIZINE HYDROCHLORIDE — FDA approval
CETIRIZINE HYDROCHLORIDE
→
Trials studying CETIRIZINE HYDROCHLORIDE
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 11, 2030
~3.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (11)
- Jan 9, 2033patentUS 9254286*PED
- Jul 9, 2032formulationUS 9254286
- Sep 15, 2030patentUS 8829005*PED4.1y
- Mar 15, 2030method-of-use (U-1680)US 88290053.6y
- Mar 15, 2030formulationUS 97506843.6y
- Mar 15, 2030method-of-use (U-1680)US 99934713.6y
- Feb 28, 2030method-of-use (U-2635)US 82635813.5y
- Feb 28, 2030method-of-use (U-2634)US 83140833.5y
- Feb 11, 2030method-of-use (U-2636)US 85132593.5y
- Feb 11, 2030method-of-use (U-2635)US 91197713.5y
- Feb 11, 2030method-of-use (U-2635)US 91800903.5y
News(1)
- Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) Issues Voluntary Nationwide Recall of Cetirizine Hydrochloride Tablets USP 5 mg Due to Potential Cross Contamination with RanitidineFOR IMMEDIATE RELEASE – July 18th, 2026 – Panoli, Gujarat, Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) is voluntarily recalling four lots of Cetirizine Hyd…fda_medwatch · 25d ago
Data sources
last refreshed 28m ago
Found something off?
comments(0)
5-min edit window · permanent after that